Literature DB >> 26037915

Two Faces of SIVA.

Lois Resnick-Silverman1, James J Manfredi2.   

Abstract

In non-small cell lung cancer cells that contain a mutated KRAS gene, SIVA, a p53 target gene that is critical for apoptosis, is overexpressed in a p53-independent manner and promotes tumorigenesis through the stimulation of mTOR signaling. The ablation of Siva in conditional knockout mice results in an inhibition of tumor development that makes SIVA an interesting new candidate therapeutic target for the treatment of a carcinoma with few therapeutic options. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26037915      PMCID: PMC4455030          DOI: 10.1158/2159-8290.CD-15-0484

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  11 in total

Review 1.  Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

Authors:  Patrick J Roberts; Thomas E Stinchcombe; Channing J Der; Mark A Socinski
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  The proapoptotic gene SIVA is a direct transcriptional target for the tumor suppressors p53 and E2F1.

Authors:  Andre Fortin; Jason G MacLaurin; Nicole Arbour; Sean P Cregan; Neena Kushwaha; Steven M Callaghan; David S Park; Paul R Albert; Ruth S Slack
Journal:  J Biol Chem       Date:  2004-04-22       Impact factor: 5.157

3.  Siva is an apoptosis-selective p53 target gene important for neuronal cell death.

Authors:  S B R Jacobs; S Basak; J I Murray; N Pathak; L D Attardi
Journal:  Cell Death Differ       Date:  2007-04-20       Impact factor: 15.828

4.  Understanding the non-canonical pathways involved in p53-mediated tumor suppression.

Authors:  Kayla M Hager; Wei Gu
Journal:  Carcinogenesis       Date:  2013-12-31       Impact factor: 4.944

5.  CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein.

Authors:  K V Prasad; Z Ao; Y Yoon; M X Wu; M Rizk; S Jacquot; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

6.  The p53 Target Gene SIVA Enables Non-Small Cell Lung Cancer Development.

Authors:  Jeanine L Van Nostrand; Alice Brisac; Stephano S Mello; Suzanne B R Jacobs; Richard Luong; Laura D Attardi
Journal:  Cancer Discov       Date:  2015-03-26       Impact factor: 39.397

Review 7.  Autophagy in cancer: good, bad, or both?

Authors:  Melanie M Hippert; Patrick S O'Toole; Andrew Thorburn
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

8.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

Authors:  David A Eberhard; Bruce E Johnson; Lukas C Amler; Audrey D Goddard; Sherry L Heldens; Roy S Herbst; William L Ince; Pasi A Jänne; Thomas Januario; David H Johnson; Pam Klein; Vincent A Miller; Michael A Ostland; David A Ramies; Dragan Sebisanovic; Jeremy A Stinson; Yu R Zhang; Somasekar Seshagiri; Kenneth J Hillan
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

Review 9.  Another fork in the road--life or death decisions by the tumour suppressor p53.

Authors:  Luis A Carvajal; James J Manfredi
Journal:  EMBO Rep       Date:  2013-04-16       Impact factor: 8.807

Review 10.  The first 30 years of p53: growing ever more complex.

Authors:  Arnold J Levine; Moshe Oren
Journal:  Nat Rev Cancer       Date:  2009-10       Impact factor: 60.716

View more
  1 in total

Review 1.  Siva-1 emerges as a tissue-specific oncogene beyond its classic role of a proapoptotic gene.

Authors:  Jiri Vachtenheim; Robert Lischke; Jiri Vachtenheim
Journal:  Onco Targets Ther       Date:  2018-10-01       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.